Tiago Fauth
Stock Analyst at Wells Fargo
(1.16)
# 3,459
Out of 4,784 analysts
142
Total ratings
30%
Success rate
-15.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $18.65 | +441.55% | 4 | Mar 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $287 | $268.46 | +6.91% | 5 | Mar 21, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Equal-Weight | $4 → $3 | $1.47 | +104.08% | 2 | Mar 4, 2025 | |
| VRNA Verona Pharma | Maintains: Overweight | $74 → $93 | $62.70 | +48.33% | 4 | Feb 28, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $28 → $26 | $10.79 | +140.96% | 6 | Feb 27, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $17 | $8.43 | +101.66% | 1 | Feb 20, 2025 | |
| INSM Insmed | Maintains: Overweight | $85 → $107 | $77.99 | +37.20% | 3 | Feb 19, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $14 → $11 | $0.92 | +1,095.39% | 2 | Jan 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $75 → $88 | $37.82 | +132.68% | 7 | Dec 20, 2024 | |
| SVRA Savara | Initiates: Overweight | $8 | $2.91 | +174.91% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.03 | +78.93% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $68 | $54.24 | +25.37% | 1 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $8.62 | +155.22% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $52.36 | +43.24% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $380 | $306.97 | +23.79% | 4 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $35 → $2 | $2.53 | -20.95% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $1.21 | +5,023.97% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $154.68 | -42.46% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $14.44 | +253.19% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $71.44 | +67.97% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $120 | $0.61 | +19,692.18% | 6 | May 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $18.37 | -78.23% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.70 | +418.52% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.30 | +1,255.47% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $7.05 | +268.79% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.31 | +1,112.12% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $24.27 | +233.75% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.37 | +2,043.05% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.06 | +1,220.75% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.66 | +5,090.05% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.42 | +4,285.96% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $36.70 | -20.98% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $2.42 | +437.19% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.25 | +940.00% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.15 | +73.91% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $589.15 | -42.29% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $306.95 | -15.62% | 1 | Apr 28, 2021 |
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $18.65
Upside: +441.55%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $275 → $287
Current: $268.46
Upside: +6.91%
Pliant Therapeutics
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.47
Upside: +104.08%
Verona Pharma
Feb 28, 2025
Maintains: Overweight
Price Target: $74 → $93
Current: $62.70
Upside: +48.33%
Keros Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $10.79
Upside: +140.96%
Amicus Therapeutics
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $8.43
Upside: +101.66%
Insmed
Feb 19, 2025
Maintains: Overweight
Price Target: $85 → $107
Current: $77.99
Upside: +37.20%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $14 → $11
Current: $0.92
Upside: +1,095.39%
Ultragenyx Pharmaceutical
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $37.82
Upside: +132.68%
Savara
Dec 20, 2024
Initiates: Overweight
Price Target: $8
Current: $2.91
Upside: +174.91%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $5.03
Upside: +78.93%
Nov 26, 2024
Maintains: Overweight
Price Target: $56 → $68
Current: $54.24
Upside: +25.37%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $8.62
Upside: +155.22%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $52.36
Upside: +43.24%
Aug 20, 2024
Maintains: Overweight
Price Target: $350 → $380
Current: $306.97
Upside: +23.79%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $2.53
Upside: -20.95%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $1.21
Upside: +5,023.97%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $154.68
Upside: -42.46%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $14.44
Upside: +253.19%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $71.44
Upside: +67.97%
May 26, 2023
Reiterates: Outperform
Price Target: $120
Current: $0.61
Upside: +19,692.18%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $18.37
Upside: -78.23%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.70
Upside: +418.52%
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.30
Upside: +1,255.47%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $7.05
Upside: +268.79%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.31
Upside: +1,112.12%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $24.27
Upside: +233.75%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.37
Upside: +2,043.05%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.06
Upside: +1,220.75%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.66
Upside: +5,090.05%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.42
Upside: +4,285.96%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $36.70
Upside: -20.98%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $2.42
Upside: +437.19%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.25
Upside: +940.00%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.15
Upside: +73.91%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $589.15
Upside: -42.29%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $306.95
Upside: -15.62%